CytoMed Therapeutics (GDTC) Non-Current Assets (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Non-Current Assets of $3.3 million for Q4 2025, down 21.97% sequentially from $4.3 million in Q2 2025, and up 15.33% YoY from $2.9 million in Q4 2024.
CytoMed Therapeutics (GDTC) Non-Current Assets (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Non-Current Assets for 5 years, with the latest figure at $3.3 million in Q4 2025.
- Quarterly Non-Current Assets rose 15.33% year-over-year to $3.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.3 million (up 15.33% YoY) and the FY2025 annual result came in at $3.3 million, down 18.66% from the prior year.
- Non-Current Assets slipped to $3.3 million in Q4 2025 per GDTC's latest filing, from $4.3 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $4.3 million in Q2 2025 and troughed at $1.5 million in Q4 2023.
- A 5-year average of $2.7 million and a median of $2.7 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2024: Non-Current Assets decreased 14.38% in 2023, then surged 87.93% in 2024.
- Over 5 years, Non-Current Assets stood at $1.9 million in 2021, then dropped by 3.53% to $1.8 million in 2022, then declined by 14.38% to $1.5 million in 2023, then jumped by 87.93% to $2.9 million in 2024, then gained by 15.33% to $3.3 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $3.3 million, $4.3 million, and $2.9 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.35 Bn | 131.50 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.12 Bn | 78.12 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.98 Bn | 53.84 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.08 Bn | 36.99 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.61 Bn | 28.30 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.59 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.47 Bn | - | 18.06 Bn |
| 10 | CytoMed Therapeutics | 9.97 Mn | 8.35 Mn | - | 3.33 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 3.33 Mn |
| Jun 30, 2025 | 4.27 Mn |
| Dec 31, 2024 | 2.89 Mn |
| Jun 30, 2024 | 3.20 Mn |
| Dec 31, 2023 | 1.54 Mn |
| Jun 30, 2023 | 2.45 Mn |
| Dec 31, 2022 | 1.80 Mn |
| Dec 31, 2021 | 1.86 Mn |